## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

## Listing of Claims

1 1. (Previously presented) A method of modulating an endothelial gene differentiation-1
("Edg-1") receptor mediated for vasoconstriction, comprising contacting a cell
expressing the Edg-1 receptor with an amount of a non-phospholipid modulator of the
Edg-1 receptor sufficient to modulate the Edg-1 receptor mediated for vasoconstriction,
wherein said modulator is a compound of Formula (Ia):

$$(R^4)_n$$

$$R^5$$

$$R^3$$

$$R^3$$

$$R^3$$

$$R^3$$

$$R^3$$

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

8 n is a member selected from the integers 0 to 5;

R1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, 9 10 acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy. alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted 12 alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted 13 aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, 14 arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, 15 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, 16 dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, 17 heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl; 18 each R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is a member independently selected from the group consisting of 19

hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted

Appl. No. 10/621,966 Amendment dated February 2, 2007 Office Action dated December 15, 2006

21 acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, 22 alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted 23 arvlalkyloxy, amino, arvl. substituted arvl. arvlalkyl, substituted arvlalkyl, 24 25 arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, 26 carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted 27 28 dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted 29 heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and 30 each R4 is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, 31 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, 32. substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, 33 34 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted 35 36 arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, 37 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted 38 39 heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted 40 heteroalkyl, hydroxyl, nitro and thio.

 (Previously presented) A method of modulating an Edg-1 receptor mediated for vasoconstriction in a subject, comprising administering to the subject a therapeutically effective amount of a non-phospholipid modulator of the Edg-1 receptor, wherein said modulator is a compound of Formula (Ia):

1

2

6 7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

21

22

23

24 25

26 27

28

R<sup>1</sup> is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted

or a pharmaceutically acceptable solvate or hydrate thereof, wherein:

n is a member selected from the integers 0 to 5;

alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl; each R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arvlalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arvlamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamovl, substituted carbamovl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted

heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio; and

each R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkyltmino, substituted alkylamino, alkyltmino, substituted alkylamino, substituted alkylamino, substituted alkylamino, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted arylalkyloxy, amino, aryl, substituted arylalkyloxy, amino, aryl, substituted arylalkyloxy, aribano, aryl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

(Canceled)

29

30

31

32

33 34

35

36

37

38 39

1

- 1 4. (Canceled)
  - 5. (Canceled)

(Canceled)

- 7. (Canceled)
- (Canceled)
- (Canceled)
- 1 10. (Canceled)
- 1 11. (Canceled)
  - (Canceled)
- 1 13. (Canceled)

- 1 14. (Canceled)
- 1 15. (Canceled)
- l 16. (Canceled)
- 1 17. (Canceled)
- 1 18. (Canceled)
- 1 19. (Canceled)
- l 20. (Canceled)
- 1 21. (Canceled)
- 22. (Canceled)
- 1 23. (Canceled)
- l 24. (Canceled)
- l 25. (Canceled)
- 1 26. (Canceled)
- 1 27. (Canceled)
- l 28. (Canceled)
- 1 29. (Canceled)
- 30. (Canceled)
- l 31. (Canceled)

- 1 32. (Canceled)
- 1 33. (Canceled)

2

3

7

8

9

10

11

12

13

14

15

16

17

18

19

20 21

34. (Previously presented) A method for treating vasoconstriction in cerebral arteries in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia) is:

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R1 is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylamino, substituted alkylamino, alkylamino, substituted alkylarylamino, substituted alkylarylamino, substituted alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, substituted cycloalkyl, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, beteroalkyl, and substituted heteroalkyl;

each R<sup>2</sup>, R<sup>3</sup> and R<sup>3</sup> is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, Appl. No. 10/621,966 Amendment dated February 2, 2007 Office Action dated December 15, 2006

alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, substituted cycloalteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroalkyl, hydroxyl, nitro and thio; and each R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkylarylamino, srylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted arylsulfonyl, substituted arylsulfonyl, azido, carboxyl, cyano.

substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted

35. (Previously presented) A method for treating vasoconstriction in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia) is:

heteroalkyl, hydroxyl, nitro and thio.

cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl,

dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted

heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

- R¹ is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylamino, substituted alkylamino, alkylamino, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;
- each R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyl, arylalkyl, substituted arylalkyl, arylamino, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, beteroaryloxy, substituted

41

42

2

3

4

5 6

7

8

30 heteroalkyl, hydroxyl, nitro and thio; each R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, 31 alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, 32 alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, 33 substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, 34 substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, 35 substituted aryl, arylalkyl, substituted arylalkyl, arylsulfonyl, substituted 36 arvisulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, 37 cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, 38 39 dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted 40

heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted

and one or more antagonists of an Edg receptor.

heteroalkyl, hydroxyl, nitro and thio;

36. (Previously presented) A method for treating in a subject in need of such treatment, said method comprising administering to said subject a therapeutically effective amount of a compound of Formula (Ia), wherein said compound of Formula (Ia) is:

$$(R^4)_n$$
 $R^5$ 
 $R^5$ 
 $R^3$ 
 $R^3$ 
 $R^3$ 

n is a member selected from the integers 0 to 5;

or a pharmaceutically acceptable solvate or hydrate thereof, wherein

R<sup>1</sup> is a member selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted

alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted arylalkyl, arylamino, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, and substituted heteroalkyl;

each R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> is a member independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylamino, alkylamino, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyl, arylamino, substituted aryl, arylalkyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroalkyl, hydroxyl, nitro and thio;

each R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylsulfonyl, substituted arylsulfonyl, azido, carboxy, carbamoyl, substituted carbamoyl, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, halo, heteroaryloxy, substituted

2

3

- heteroaryloxy, heteroaryl, substituted heteroaryl, heteroalkyl, substituted
   heteroalkyl, hydroxyl, nitro and thio;
- 41 and one or more drugs useful in treating vasoconstriction.
  - 37. (Previously presented) The method of Claim 1 or 2, wherein the modulator is a compound of a formula that is selected from:

5

- 1 38. (Canceled)
- 1 **39.** (Canceled)
- 1 40. (Canceled)
- 1 41. (Canceled)
- 1 42. (Canceled)
- 1 43. (Canceled)
- 1 44. (Canceled)

- 1 45. (Canceled)
  1 46. (Canceled)
  1 47. (Canceled)
  1 48. (Canceled)
- 1 50. (Canceled)

(Canceled)

49.

4

6

7

8

9

10

11

1 51. (Previously presented) A method of treating vasoconstriction in a patient comprising:
2 administering to the patient a therapeutically effective amount of a modulator of an Edg-1
3 receptor wherein the modulator is a compound of Formula (Ib) is:

5 or a pharmaceutically acceptable solvate or hydrate thereof, wherein

n is a member selected from the integers 0 to 5;

R11 is an aryl group;

each R<sup>2</sup> and R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkylamino, substituted alkylamino, alkylthio, substituted alkylamino, alkylthio, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted

arylalkyloxy, amino, aryl, substituted aryl, arylallcyl, substituted arylalkyl,
arylamino, substituted arylamino, arylsulfonyl, substituted arylsulfonyl, carboxy,
carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl,
cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted
dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted
heteroaryl, heteroalkyl, substituted heteroalkyl, hydroxyl, nitro and thio.

- 52. (Previously presented) The method of claim 51, wherein said aryl group in R<sup>11</sup> is a
   heteroaryl group.
- 1 53. (Previously presented) The method of claim 52, wherein said compound has the formula:

- 1 54. (Previously presented) The method of claim 53, wherein R<sup>2</sup> is a substituted alkyl group.
- 55. (Previously presented) The method of claim 54, wherein R<sup>2</sup> is said substituted alkyl
   group is -CF<sub>3</sub>.
- 1 56. (Previously presented) The method of claim 55, wherein n is 1.
- 1 57. (Previously presented) The method of claim 56, wherein R<sup>4</sup> is a halo group.
- 1 58. (Previously presented) The method of claim 57, wherein said halo group is chlorine.
- (Previously presented) A method of treating vasoconstriction in a patient comprising:
   administering to the patient a therapeutically effective amount of a modulator of an Edg-1
   receptor wherein the modulator is a compound of Formula (Ic):

n is a member selected from the integers 0 to 5;

- each R<sup>4</sup> is a member independently selected from the group consisting of hydrogen, halo, alkyl, substituted alkyl, acyl, substituted acyl, acylamino, substituted acylamino, alkyltmino, substituted alkylamino, alkyltmino, substituted alkylamino, alkoxy, substituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl, alkylarylamino, substituted alkylarylamino, arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylallcyl, substituted arylalkyl, arylamino, substituted arylamino, arylsulfonyl, substituted arylamino, carboxy, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, dialkylamino, substituted dialkylamino, heteroaryloxy, substituted heteroaryloxy, heteroaryl, substituted heteroaryl, heteroaryl, substituted heteroaryl, nitro and thio.
- 1 60. (Previously presented) The method of claim 59, wherein n is 1.
  - 61. (Previously presented) The method of claim 60, wherein R<sup>4</sup> is a halo group.
  - 62. (Previously presented) The method of claim 61, wherein said halo group is chlorine.
  - 63. (Canceled)

5

2

3

4

5

6

7

8

9

10

12

1

64. (Canceled)